Listen for Questions About the Safety of Ranitidine and Other Meds

November 2019

Headlines about a probable carcinogen in some Rx and OTC ranitidine products will raise questions about the safety of generic and brand meds.

The buzz is about N-nitrosodimethylamine (NDMA)...the impurity that first sparked recalls of irbesartan, losartan, and valsartan.

Now FDA is investigating how much NDMA is in ranitidine...whether it poses any risk...and the source. In fact, one lab's analysis used high temps to test ranitidine...and the test itself generated NDMA.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Med Histories Avoid Common Pitfalls With Med Lists
Med Safety Listen for Questions About the Safety of Ranitidine and Other Meds
Diabetes Think of Rybelsus as the Tablet Version of Injectable Ozempic
Medication Errors Double-Check Microgram and Milligram Calculations
Alcohol Stay Alert for Patients Talking About Drinking Alcohol While on Meds
HIV & AIDS Don't Be Surprised to See Descovy Used to Prevent HIV
Hypoglycemia Be Ready to Dispense New Glucagon Products for Very Low Blood Sugar
Dermatology Steer Patients Looking for Scar Treatments to the Pharmacist
Breast Cancer Reduce Errors With Breast Cancer Prevention Meds
Pain Management Watch for Med Changes to Treat Acute Pain for Patients on Buprenorphine/Naloxone
Medicare Pay Close Attention to Medicare Rxs for DME

Listen for Questions About the Safety of Ranitidine and Other Meds

Practical advice for a better career, with unlimited access to CE

Table of Contents